Cited by 103Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesCancer-related Molecular Pathways

The DOI matches its Crossref record; 129 of the 132 references it cites were found in a registry or an index.

Current status and new treatment approaches in TP53 mutated AML

Hunter, Anthony M., Sallman, David A.·2019·Best Practice & Research Clinical Haematology

DOI 10.1016/j.beha.2019.05.004

Open this paper in CoChat — free account

Abstract

Mutations in the essential tumor suppressor gene, TP53, are observed in only 5-10% of acute myeloid leukemia (AML) cases, but are highly associated with therapy-related AML and cases with complex karyotype. The mutational status of TP53 is a critical prognostic indicator, with dismal outcomes consistently observed across studies. Response rates to traditional cytotoxic chemotherapy are poor and long-term survival after allogeneic hematopoietic stem cell transplant is rare. Therapy with hypomethylating agents has resulted in a modest improvement in outcomes over intensive chemotherapy, but durable responses are seldom observed. In view of the intrinsic resistance to standard chemotherapies conferred by mutations in TP53, novel treatment approaches are required. In this review, we examine the current treatment landscape in TP53 mutated AML and discuss emerging therapeutic approaches currently under clinical investigation.

Integrity signals

Registry

Crossref · 10.1016/j.beha.2019.05.004

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,938
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy
Christman, J. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205699 · Cited by 1,561
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S. B., McClatchey, A. I., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,468
Post-translational modification of p53 in tumorigenesis
Bode, A. M., & Dong, Z. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1455 · Cited by 1,270
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Kantarjian, H. M., Thomas, X., Dmoszyńska, A., Wierzbowska, A., Mazur, G. J., Mayer, J., Gau, J., Chou, W., Buckstein, R. J., Čermák, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,170
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D. E., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,031
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R. A., Hogdal, L. J., Benito, J. M., Bucci, D. M., Han, L., Borthakur, G. M., Cortes, J. E., DeAngelo, D. J., Debose, L., Mu, H. H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 734
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Hills, R. K., Castaigné, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S. H., Othus, M. K. D., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 733
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Rücker, F. G., Schlenk, R. F., Bullinger, L., Käyser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2011) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 694
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C. L., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y., McSweeney, P. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 595
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Daver, N. G., Garcia‐Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M. Y., Ravandi‐Kashani, F., Jabbour, E. J., Kadia, T. M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 571
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Cashen, A. F., Schiller, G. J., O'Donnell, M. R., & DiPersio, J. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9178 · Cited by 464
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Blum, W. G., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S. M., Liu, S., Havelange, V., Becker, H., Schaaf, L. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
Ritchie, D. S., Neeson, P. J., Khot, A. S., Peinert, S., Tai, T. Y., Tainton, K. M., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 448
p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression
Moon, S.-H., Huang, C., Houlihan, S. L., Regunath, K., Freed-Pastor, W. A., Morris, J. P., Tschaharganeh, D. F., Kastenhuber, E. R., Barsotti, A. M., Culp‐Hill, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.011 · Cited by 447
Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
de Lima, M., Giralt, S., Thall, P. F., Silva, L. D. P., Jones, R. B., Komanduri, K. V., Braun, T. M., Nguyen, H. Q., Champlin, R. E., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Wang, Q., Wang, Y., Lv, H., Han, Q., Fan, H., Guo, B., Wang, L.-L., & Han, W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 424
Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Bejar, R. L., Stevenson, K. E., Caughey, B. A., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G. A., Steensma, D. P., Ritz, J., Soiffer, R. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 403
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Hollenbach, P. W., Nguyen, A. N., Brady, H. A., Williams, M. M., Ning, Y., Richard, N., Krushel, L. A., Aukerman, S. L., Heise, C. C., & MacBeth, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009001 · Cited by 362
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 359
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Vo, T.-T. T., Ryan, J. A., Carrasco, R. D., Neuberg, D. S., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. G. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 356
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima‐Yamashita, Y., Yoshida, K., Shiraishi, Y., Suzuki, H., Nagata, Y., Sato, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-754796 · Cited by 352
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Baumeister, S. H. C., Murad, J., Werner, L. L., Daley, H., Trebeden‐Negre, H., Gicobi, J. K., Schmucker, A. C., Reder, J., Sentman, C. L., Gilham, D. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0307 · Cited by 334
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer · doi:10.1002/cncr.31896 · Cited by 330
Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
Li, D., Marchenko, N. D., Schulz‐Heddergott, R., Fischer, V., Velasco-Hernández, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 309
Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor Prognosis
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos, A. G., Kerr, R. S., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., & Young, L. S. (1995) · PubMed · Cited by 296
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G. M., Jabbour, E. J., Konopleva, M. Y., Daver, N. G., et al. (2016) · Cancer · doi:10.1002/cncr.30203 · Cited by 271
Implications of the p53 tumor-suppressor gene in clinical oncology.
Chang, F., Syrjänen, S., & Syrjänen, K. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.1009 · Cited by 264
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Porta, M. G. D., Gallì, A., Bacigalupo, A. P., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., Lint, M. T. V., Pioltelli, P. E., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 261
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259
Self-citation
A novel hierarchical prognostic model of AML solely based on molecular mutations
Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C., Staib, P., Serve, H. L., et al. (2012) · Blood · doi:10.1182/blood-2012-03-419622 · Cited by 253
TP 53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype
Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W., & Haferlach, T. (2008) · Leukemia · doi:10.1038/leu.2008.143 · Cited by 247
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Parrales, A., Ranjan, A., Iyer, S. V., Padhyé, S., Weir, S. J., Roy, A., & Iwakuma, T. (2016) · Nature Cell Biology · doi:10.1038/ncb3427 · Cited by 239
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Lübbert, M., Rüter, B. H., Claus, R., Schmoor, C., Schmid, M., Germing, U., Kuendgen, A., Rethwisch, V., Ganser, A., Platzbecker, U., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.048231 · Cited by 232
Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231
Self-citation
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 230
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Li, L., Hoog, J., Goiffon, R., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 227
TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis
Bowen, D., Groves, M. J., Burnett, A. K., Patel, Y., Allen, C. G., Green, C. L., Gale, R. E., Hills, R. K., & Linch, D. C. (2008) · Leukemia · doi:10.1038/leu.2008.173 · Cited by 214
Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 190
Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile
Schoch, C., Kern, W., Kohlmann, A., Hiddemann, W., Schnittger, S., & Haferlach, T. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20193 · Cited by 188
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Craddock, C., Jilani, N., Siddique, S., Yap, C., Khan, J., Nagra, S., Ward, J., Ferguson, P., Hazlewood, P., Buka, R. J., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.09.004 · Cited by 177
Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial
Budde, L. E., Song, J. Y., Kim, Y., Blanchard, S., Wagner, J. R., Stein, A. S., Weng, L., Real, M. M. D., Hernandez, R., Marcucci, E. C., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.811.811 · Cited by 176
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
Hou, H.-A., Chou, W.-C., Kuo, Y.-Y., Liu, C.-Y., Lin, L., Tseng, M.-H., Chiang, Y.-C., Liu, M.-C., Liu, C.-W., Tang, J.-L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.59 · Cited by 167
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Pusic, I., Choi, J., Fiala, M. A., Gao, F., Holt, M. S., Cashen, A. F., Vij, R., Abboud, C. N., Stockerl-Goldstein, K. E., Jacoby, M. A., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.026 · Cited by 164
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance
Martirosyan, A., Clendening, J. W., Goard, C. A., & Penn, L. Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-103 · Cited by 160
The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia
Seifert, H., Mohr, B., Thiede, C., Oelschlägel, U., Schäkel, U., Illmer, T., Soucek, S., Ehninger, G., Schaich, M. A., & on behalf of the Study Alliance Leukemia (SAL) (2009) · Leukemia · doi:10.1038/leu.2008.375 · Cited by 158
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
Ok, C. Y., Patel, K. P., Garcia‐Manero, G., Routbort, M. J., Peng, J., Tang, G., Goswami, M., Young, K. H., Singh, R. R., Medeiros, L. J., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0139-z · Cited by 144
Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations
Ohgami, R. S., Ma, L., Merker, J. D., Gotlib, J. R., Schrijver, I., Zehnder, J. L., & Arber, D. A. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.160 · Cited by 141
First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial
Liu, F., Cao, Y., Pinz, K. G., Ma, Y., Wada, M., Chen, K., Ma, G., Shen, J., Tse, C. O., Su, Y., et al. (2018) · Blood · doi:10.1182/blood-2018-99-110579 · Cited by 141
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140
Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
Issa, J. J., Garcia‐Manero, G., Huang, X., Cortes, J. E., Ravandi, F., Jabbour, E. J., Borthakur, G. M., Brandt, M., Pierce, S. A., & Kantarjian, H. M. (2014) · Cancer · doi:10.1002/cncr.29085 · Cited by 139
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Döhner, H., Dolnik, A., Tang, L., Seymour, J. F., Minden, M. D., Stone, R. M., Bernal, T., Al‐Ali, H. K., Santini, V., Vyas, P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0257-z · Cited by 132
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Kirschbaum, M. H., Gojo, I., Goldberg, S. L., Bredeson, C., Kujawski, L. A., Yang, A. S., Marks, P. W., Frankel, P. H., Sun, X. G., Tosolini, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13016 · Cited by 131
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126
Immunohistochemical correlates of TP53 somatic mutations in cancer
Murnyák, B., & Hortobágyi, T. (2016) · Oncotarget · doi:10.18632/oncotarget.11912 · Cited by 121
Mutations of the P53 gene in acute myeloid leukaemia
Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveaux, P., Laı̈, J. L., Vanrumbeke, M., Loucheux‐Lefebvre, M. H., Bauters, F., Berger, R., & Kerckaert, J. P. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08897.x · Cited by 117
Thep53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers
Hamada, M., Fujiwara, T., HIZUTA, A., Gochi, A., Naomoto, Y., Takakura, N., Takahashi, K., Roth, J. A., Tanaka, N., & Orita, K. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01220804 · Cited by 115
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Kuykendall, A. T., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 115
Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Kim, M., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 113
Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells
Cummins, K. D., Frey, N. V., Nelson, A. M., Schmidt, A. H., Luger, S. M., ISAACS, R. E., Lacey, S. F., Hexner, E. O., Melenhorst, J. J., June, C. H., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1359.1359 · Cited by 111
TP 53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
Middeke, J. M., Herold, S., Rücker‐Braun, E., Berdel, W. E., Stelljes, M., Kaufmann, M., Schäfer‐Eckart, K., Baldus, C. D., Stuhlmann, R., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13912 · Cited by 101
Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study
Prébet, T., Sun, Z., Ketterling, R. P., Zeidan, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Smith, M. R., Malick, L., Paietta, E. M., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13832 · Cited by 99
Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature
Craddock, C. F., Houlton, A. E., Quek, L. S., Ferguson, P., Gbandi, E., Roberts, C., Metzner, M., Garcia-Martin, N., Kennedy, A., Hamblin, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1423 · Cited by 88
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms
Au, C. H., Wa, A., Ho, D. N., Chan, T. L., & Ma, E. S. K. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0456-8 · Cited by 87
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
Bug, G., Burchert, A., Wagner, E.-M., Kröger, N. M., Berg, T., Gueller, S., Metzelder, S., Wolf, A., Hünecke, S., Bader, P., et al. (2017) · Leukemia · doi:10.1038/leu.2017.242 · Cited by 85
An open-label phase I dose-finding study of APR-246 in hematological malignancies
Deneberg, S., Cherif, H., Lazarevic, V, Andersson, P.-O., von Euler, M., Juliusson, G., & Lehmann, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.60 · Cited by 84
Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3
Baldwin, A. E., Grueneberg, D. A., Hellner, K., Sawyer, J., Grace, M. R., Li, W., Harlow, E., & Münger, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007462107 · Cited by 83
The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine
Nieto, M. D., Samper, E., Fraga, M. F., de Buitrago, G. G., Esteller, M., & Serrano, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207175 · Cited by 83
Molecularly targeted therapies for p53-mutant cancers
Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 82
Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion
Sebaa, A., Adès, L., Baran‐Marszak, F., Mozziconacci, J., Penther, D., Dobbelstein, S., Stamatoullas, A., Récher, C., Prébet, T., Moulessehoul, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21993 · Cited by 81
Role ofASXL1andTP53mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
Devillier, R., Mas, V. M., Gelsi‐Boyer, V., Demur, C., Murati, A., Corre, J., Prébet, T., Bertoli, S., Brecqueville, M., Arnoulet, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3460 · Cited by 81
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
Sallman, D. A., Brayer, J. B., Sagatys, E. M., Lonez, C., Breman, E., Agaugué, S., Verma, B., Gilham, D. E., Lehmann, F. F., & Davila, M. L. (2018) · Haematologica · doi:10.3324/haematol.2017.186742 · Cited by 81
Self-citation
TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers
Győrffy, B., Bottai, G., Lehmann‐Che, J., Kéri, G., Őrfi, L., Iwamoto, T., Desmedt, C., Bianchini, G., Turner, N. C., de Thé, H., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.018 · Cited by 80
Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells
Origanti, S., Cai, S.-R., Munir, A. Z., White, L. S., & Piwnica-Worms, H. (2013) · Oncogene · doi:10.1038/onc.2012.84 · Cited by 74
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
Ali, D., Jönsson‐Videsäter, K., Deneberg, S., Bengtzén, S., Nahi, H., Paul, C., & Lehmann, S. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01557.x · Cited by 70
Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
McGraw, K. L., Nguyen, J., Komrokji, R. S., Sallman, D. A., Ali, N. H. A., Padron, E., Lancet, J. E., Moscinski, L. C., List, A. F., & Zhang, L. (2016) · Haematologica · doi:10.3324/haematol.2016.143214 · Cited by 68
Self-citation
A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)
Garcia‐Manero, G., Sasaki, K., Bravo, G. M., Daver, N. G., Jabbour, E. J., Alvarado, Y., Dinardo, C. D., Ravandi, F., Borthakur, G. M., Bose, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119424 · Cited by 68
Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Sallman, D. A., Dezern, A. E., Steensma, D. P., Sweet, K. L., Cluzeau, T., Sekeres, M. A., Garcia‐Manero, G., Roboz, G. J., McLemore, A. F., McGraw, K. L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119990 · Cited by 66
Self-citation
Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis
Fernandez‐Pol, S., Ma, L., Ohgami, R. S., & Arber, D. A. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.206 · Cited by 63
PRIMA‐1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
Nahi, H., Merup, M., Lehmann, S., Bengtzén, S., Möllgård, L., Selivanova, G., Wiman, K. G., & Paul, C. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05851.x · Cited by 62
Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?
Tasian, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718774268 · Cited by 60
Decitabine inTP53-Mutated AML
Welch, J. S., Petti, A. A., & Ley, T. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616062 · Cited by 56
A targeted next‐generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice
Lin, P., Li, H., Fan, S., Yuan, T., Chen, M., Hsu, Y., Yang, Y., Li, L., Yeh, S., Bai, L., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.969 · Cited by 53
TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
Goldberg, A. D., Talati, C., Desai, P. M., Famulare, C. A., Devlin, S. M., Farnoud, N. R., Sallman, D. A., Lancet, J. E., Roboz, G. J., Sweet, K. L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117772 · Cited by 44
Self-citation
Acute myeloid leukemia targets for bispecific antibodies
Hoseini, S. S., & Cheung, N. V. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.2 · Cited by 44
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Kadia, T. M., Cortes, J. E., Ghorab, A., Ravandi, F., Jabbour, E. J., Daver, N. G., Alvarado, Y., Ohanian, M. N., Konopleva, M. Y., & Kantarjian, H. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.7014 · Cited by 43
Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells
Yi, L., Sun, Y., & Levine, A. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2441 · Cited by 39
Erratum: Acute myeloid leukemia targets for bispecific antibodies
Hoseini, S. S., & Cheung, N. V. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.35 · Cited by 38
Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells
Nishioka, C., Ikezoe, T., Yang, J., Udaka, K., & Yokoyama, A. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.04.004 · Cited by 34
TP53 mutations in older adults with acute myeloid leukemia
Yanada, M., Yamamoto, Y., Iba, S., Okamoto, A., Inaguma, Y., Tokuda, M., Morishima, S., Kanie, T., Mizuta, S., Akatsuka, Y., et al. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1942-1 · Cited by 34
Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Oran, B., Lima, M. J. G. D., Garcia‐Manero, G., Thall, P. F., Lin, R., Alousi, A. M., Hosing, C. M., Kebriaei, P., Popat, U., Giralt, S. A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111582 · Cited by 31
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
Ungerstedt, J. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103091 · Cited by 30
Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy
Sallman, D. A., Kerre, T. C. C., Poiré, X., Havelange, V., Lewalle, P., Davila, M. L., Wang, E. S., Dekker, D., Snykers, S., Sotiropoulou, P. A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111326 · Cited by 26
Self-citation
Statins induce lethal effects in acute myeloblastic leukemia cells within 72 hours
Burke, L. P., & Kukoly, C. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701760011 · Cited by 25
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia
Min, C., Moore, N., Shearstone, J. R., Quayle, S. N., Huang, P., van Duzer, J. H., Jarpe, M. B., Jones, S. S., & Yang, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169128 · Cited by 24
Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor
Terada, K., Yamaguchi, H., Ueki, T., Usuki, K., Kobayashi, Y., Tajika, K., Gomi, S., Kurosawa, S., Miyadera, K., Tokura, T., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3143-2 · Cited by 17
Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study
Daver, N. G., Garcia‐Manero, G., Basu, S., Cortes, J. E., Ravandi, F., Kadia, T. M., Konopleva, M. Y., Jabbour, E. J., Dinardo, C. D., Assi, R. E., et al. (2018) · Blood · doi:10.1182/blood-2018-99-120157 · Cited by 16
Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
Garcia‐Manero, G., Bravo, G. M., Sasaki, K., Daver, N. G., Jabbour, E. J., Alvarado, Y., Dinardo, C. D., Ravandi, F., Borthakur, G. M., Bose, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-118948 · Cited by 14
Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
Sallman, D. A., Al Ali, N., Yun, S., Padron, E., Song, J., Hussaini, M. O., Talati, C., Sweet, K. L., Lancet, J. E., List, A. F., et al. (2018) · Blood · doi:10.1182/blood-2018-99-117297 · Cited by 12
Self-citation
Nivolumab for Relapsed or Residual Haematological Malignancies after Allogeneic Haematopoietic Stem Cell Transplantation (NIVALLO)
Wong, E. Y. L., Dawson, E., Davis, J. E., Koldej, R. M., Ludford‐Menting, M., Lansdown, M., Lambie, H., Szer, J., Grigg, A., & Ritchie, D. (2018) · Blood · doi:10.1182/blood-2018-99-112310 · Cited by 12
Transplantation for therapy-related, TP53 -mutated myelodysplastic syndrome – not because we can, but because we should
Cutler, C. S. (2017) · Haematologica · doi:10.3324/haematol.2017.181180 · Cited by 10
Molecular predictors of post-transplant survival in acute myeloid leukemia
Qin, T., Wu, S., Zhao, H., Xu, K., Fu, H., Cheng, Z., Pang, Y., Han, Y., Chen, L., Wang, C., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0027-6 · Cited by 9
Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study
Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G. M., Kadia, T. M., Daver, N. G., Ohanian, M. N., Dinardo, C. D., et al. (2018) · Blood · doi:10.1182/blood-2018-99-115367 · Cited by 9
Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype
Sallman, D. A., McLemore, A. F., Komrokji, R. S., McGraw, K. L., Geyer, S. M., Eksioglu, E. A., Ali, N. E. A., Lancet, J. E., Wei, S., Padron, E., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.423.423 · Cited by 6
Self-citation
A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial
Dennis, M. W., Hills, R. K., Thomas, I., Gupta, S., Panoskaltsis, N., Copland, M., Burnett, A. K., & Russell, N. H. (2016) · Blood · doi:10.1182/blood.v128.22.2827.2827 · Cited by 3

Sorted by citations

Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
“PRD (63-97) DBD (102-292) TET (323-356) REG (363-393) TAD2 (43-62) TAD1 (1-42) CR mCR + HI mCR HI SD PD NR/NE”
Self-citation
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 461
Unified classification and risk-stratification in Acute Myeloid Leukemia
Tazi, Y., Ossa, J. A., Zhou, Y., Bernard, E., Thomas, I., Gilkes, A., Freeman, S. D., Pradat, Y., Johnson, S. J., Hills, R. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32103-8 · Cited by 195
TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 184
Self-citation
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer · doi:10.1002/cncr.33689 · Cited by 161

See all 103

Authors: Hunter, A. M., & Sallman, D. A.
Affiliations: University of South Florida (US)
Moffitt Cancer Center (US)
Corresponding author: Sallman, David A.
ORCID: Hunter, Anthony M.
Sallman, David A.
Venue: Best Practice & Research Clinical Haematology
Publisher: Elsevier BV
Published: 2019-06
Volume: 32
Issue: 2
Pages: 134-144
ISSN: 1521-6926 (ISSN-L)
DOI: 10.1016/j.beha.2019.05.004
OpenAlex: W2944248311
Cited by: 102
References: 132
Citations by year: 2026: 5 · 2025: 8 · 2024: 11 · 2023: 20 · 2022: 19 · 2021: 26 · 2020: 10 · 2019: 2
FWCI: 2.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Best Practice & Research Clinical Haematology (publishedVersion)
PubMed (publishedVersion)
Funders: Celgene
Jazz
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords: TP53 mutation, acute myeloid leukemia, therapy-related AML, complex karyotype, prognostic factors, chemoresistance, hypomethylating agents, allogeneic hematopoietic stem cell transplantation, novel therapeutic approaches, targeted therapy
MeSH terms: Humans, Mutation, Time Factors, Leukemia, Myeloid, Acute, Survival Rate, Tumor Suppressor Protein p53, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Current status and new treatment approaches in TP53 mutated AML

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks